Supplementary Table 1 | Studies demonstrating prognostic implications of LGE and T1 mapping
Population
177 patients with known CAD and scar tissue on
LGE CMR
231 patients with healed MI (>3 months after
MI)
1,148 patients with known or suspected CAD
195 patients without a known previous MI and
signs or symptoms of CAD
100 patients with CAD
44 patients with CMR 10±6 days after infarction
281 patients with acute STEMI and primary
angioplasty 4.3 days after the acute event
184 patients within the week after successfully
reperfused first acute MI
438 patients with STEMI reperfused by primary
angioplasty <12 h after symptom onset
208 patients with STEMI undergoing primary
angioplasty <12 h after symptom onset
47 patients before ICD implantation for primary
prevention of SCD
91 patients with previous MI scheduled for ICD
implantation
144 patients with documented CAD and LGE
consistent with MI
184 patients with DCM
65 NICM patients with a left ventricular ejection
fraction ≤35%
137 patients with nonischaemic DCM
243 patients with HCM
424 patients with HCM without a history of
septal ablation or myectomy
47 patients with suspected cardiac amyloidosis
664 patients without known previous MI
referred for radiofrequency ablation of atrial
fibrillation
1,644 patients with systemic hypertension and
known or suspected CAD (no previous MI)
187 diabetic patients with or without MI
793 patients without amyloidosis or HCM
231 diabetic patients without amyloidosis
61 patients with HF with preserved ejection
fraction without amyloidosis or sarcoidosis
101 patients with DCM
Measure of fibrosis
LGE size
Outcomes
Cardiac and noncardiac death or nonfatal MI at
1.7 years
All-cause mortality at 1.7 years
Study
MACE at 2.6 years
MACE and cardiac mortality at 1.3 years
42
LGE size
Presence of MVO,
LGE size
Extent of MVO, LGE
size
Presence/ persistent
MVO
Presence and extent
of late MVO
Myocardial salvage
All-cause mortality at 4.8 years
2 year cardiovascular morbidity or mortality
44
All-cause mortality, recurrent MI, or congestive HF
requiring hospitalization
MACE at 1 year
51
Death, nonfatal MI, or congestive HF at 1.6 years
53
MACE at 0.5 years
55
Grey-zone size
Inducibility for monomorphic VT
56
Grey-zone size
Spontaneous ventricular arrhythmia with subsequent
ICD therapy
All-cause mortality and cardiovascular mortality at
2.4 years
Cardiac death, hospitalization for congestive HF, or
appropriate ICD discharge at 1.8 years
Cardiac death, hospitalization for HF, or ICD discharge
at 1.4 years
VT, ICD intervention, or VF and SCD at 3 years
All-cause or cardiac mortality at 3 years
SCD or appropriate implanted ICD therapy at 3.6 years
58
LGE size,
transmurality
Presence of LGE
Presence of LGE
Grey-zone size
Presence of LGE
Presence of LGE
Presence of LGE
Presence of LGE
Presence of LGE
40
41
43
50
52
60
63
64
65
69
72
Presence of LGE
All-cause mortality at 1 year
Presence and size of All-cause mortality at 3.6 years
LGE
75
Presence and size of MACE at 2.4 years
LGE
Presence of LGE
MACE at 1.4 years
ECV
All-cause mortality and composite (death, cardiac
transplantation, or left ventricular assist device
implantation) at 0.8 years
ECV
Mortality or hospitalization for HF at 1.3 years
Postcontrast T1
Hospitalization for HF or cardiac death at 1.5 years
84
83
85
151
141
123
156
Presence of midAll-cause death or hospitalization at 1.8 years
wall LGE
Abbreviations: CAD, coronary artery disease; CMR, cardiac magnetic resonance; DCM, dilated cardiomyopathy; HCM, hypertrophic
cardiomyopathy; HF, heart failure; ICD, implantable cardioverter defibrillator; LGE, late gadolinium enhancement; MACE, major adverse
cardiac event; MI, myocardial infarction; MVO, microvascular obstruction; SCD, sudden cardiac death; STEMI, ST-segment elevation
myocardial infarction; VF, ventricular fibrillation; VT, ventricular tachycardia.
Supplementary reference
Assomull, R. G. et al. Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. J. Am. Coll.
Cardiol. 48, 1977–1985 (2006).
156.